Insmed Japan to Capitalize on Arikayce, Pins Hopes on Brensocatib: New President

July 5, 2023
Insmed Japan President Makoto Nakamura Insmed’s key medium-term goal in Japan is to maximize the value of its Mycobacterium avium complex (MAC) lung disease drug Arikayce (amikacin), the company’s first product released in the country, says Makoto Nakamura, who was...read more